

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**29 July 2023 :: Issue 713**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## Milestones, Perspectives



### [The Big Catch-Up: An Essential Immunization Recovery Plan for 2023 and Beyond](#)

WHO 26 July 2023 :: 24 pages

PDF: <https://apps.who.int/iris/rest/bitstreams/1521937/retrieve>

#### Overview

The backsliding of immunization coverage during the COVID-19 pandemic, combined with delayed catch-up efforts has resulted in a large and growing immunity gap. There is an urgent need to close this gap, and enable millions of missed children to be vaccinated. The Essential Immunization Recovery Plan sets out a path to getting immunization back on track, framed by three key approaches – *Catch-Up, Restore and Strengthen*.

This document serves as the joint strategic description of this coordinated effort by WHO, UNICEF, and Gavi, the Vaccine Alliance, along with the Immunization Agenda 2030 (IA2030) Partnership, to support countries to plan and implement intensified efforts to bolster immunization programmes in 2023 and beyond.

Our strategy is driven by three core objectives:

1

#### CATCH-UP

Reach children who missed vaccination during the period 2019–2022, which was partly due to the pandemic, and provide all missing vaccinations.

2

#### RESTORE

Restore vaccination coverage rates for the current birth cohort in 2023 to at least 2019 levels.

3

#### STRENGTHEN

Strengthen immunization systems within PHC approaches, to improve programme resilience and accelerate towards reaching zero-dose children in line with IA2030 and Gavi 5.1 goals and targets.



### [WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis](#)

*New Model Essential List published today reaches a record number of medicines listed*

26 July 2023 News release

**Today the World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc) which include important new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions, among others.** The updated Model Lists aim to facilitate greater access to innovative medicines that show clear clinical benefits. These treatments

could have a very large public health impact globally without jeopardizing the health budgets of low- and middle-income countries.

“For over 40 years, countries all over world have relied on the WHO Essential Medicines List as a definitive, evidence-based guide the most important medicines for delivering the biggest health impact,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Rising prices and supply chain disruptions mean that all countries now face increasing problems in ensuring consistent and equitable access to many quality-assured essential medicines. WHO is committed to supporting all countries to overcome these obstacles to increase access with equity.”

**For the 2023 update, 85 applications, encompassing over one hundred medicines and formulations, were considered** by the WHO Expert Committee on Selection and Use of Essential Medicines. The recommended changes bring the **total number of medicines on the EML and EMLc to 502 and 361, respectively.**

Full details of the Expert Committee’s recommendations, describing the additions, changes and removal of medicines, and decisions not to recommend medicines are available in the Executive Summary [here](#).

### ***...Infectious diseases***

New medicines listed for infectious diseases include:

- ceftolozane + tazobactam, a ‘reserve’ group antibiotic effective against multi-drug resistant bacteria, including difficult-to-treat infections caused by carbapenem resistant *Pseudomonas aeruginosa*;
- pretomanid for treatment of multidrug-resistant or rifampicin-resistant tuberculosis;
- ravidasvir (to be used in combination with sofosbuvir) for the treatment of chronic hepatitis C virus infection in adults;
- monoclonal antibodies for Ebola virus disease.

### ***...Section 19: Immunologicals***

Section 19.3 Vaccines

This section was reviewed by the Secretariat for consistency and full alignment with the latest WHO recommendations for routine immunization (March 2023). No changes to the current vaccine listings on the EML and EMLc were required.

.....  
.....

## **[Pandemic Fund Allocates First Grants to Help Countries Be Better Prepared for Future Pandemics](#)**

World Bank, July 20, 2023

**The Pandemic Fund’s Governing Board has approved grants under its first round of funding allocations aimed to boost the resilience to future pandemics in 37 countries across six regions.** The selected projects will receive funding to strengthen disease surveillance and early warning, laboratory systems, and health workforce.

Established in September 2022, and formally launched under Indonesia’s G20 Presidency at the G20 meetings in Bali, Indonesia last November, the **Pandemic Fund is the first multilateral financing mechanism dedicated to providing multiyear grants to help low- and middle-income**

**countries become better prepared for future pandemics.** The Fund, which is hosted by the World Bank, has already raised \$2 billion in seed capital from 25 sovereign and philanthropic contributors. In May of this year, the Pandemic Fund closed its first Call for Proposals and received 179 applications from 133 countries.

**The Pandemic Fund’s Governing Board met on July 19, 2023 to make its allocation decision under the first Call, based on the technical recommendations of the independent Technical Advisory Panel (TAP).** Based on the proposals recommended by TAP, 19 were selected by the Board, with a focus on the three priority areas of the first Call for Proposals and will benefit 37 countries representing all World Bank geographic regions, with at least 2 projects allocated per region. About 30% of the grants allocated are for projects in sub-Saharan Africa – the region with the highest demand for Pandemic Fund grants. **Over 75% of the projects supported by the first Call are in low and lower-middle income countries.** The projects involve a variety of Implementing Entities. These projects support the Pandemic Fund’s objectives to bring additional, dedicated resources for pandemic prevention, preparedness, and response, incentivize countries to increase investments, enhance coordination among partners, and serve as a platform for advocacy...

In keeping with the Pandemic Fund’s mission to catalyze funding and promote coordination, **the \$338 million of grants awarded will mobilize over \$2 billion in additional resources**, adding \$6 for each \$1 coming from the Fund. Many of the projects involve collaboration between countries, UN agencies and Multilateral Development Banks. In responding to this call for proposals, countries have mobilized civil society and networks of delivery partners. Many of the projects involve cross-border and regional collaboration, a One Health approach— a collaborative approach that combines human, animal and ecosystem health, and consideration for gender and equity...

The Pandemic Fund’s Governing Board aims to launch the second Call for Proposals by the end of 2023, based on lessons learned from the first Call for Proposals. A listing of all grants awarded under the first call at available at the title link above.

.....  
.....

### ***Editor’s Note***

In last week’s edition, we featured a newly-commissioned report – [\*\*Trends in Global Adult Vaccination: Impact of COVID-19 - RESEARCH BRIEF, July 2023\*\*](#) by the [IQVIA Institute for Human Data Science](#). The report was undertaken in collaboration with the [Global Coalition in Aging \[GCOA\]](#) and funded by GSK. The full report is available upon registration[no fee] here: <https://www.iqvia.com/insights/the-iqvia-institute/reports/trends-in-global-adult-vaccination>

The report’s modelling estimates that **“approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated**, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.” *[see media release excerpt below]*

Recognizing that public data on adult vaccinations globally is very limited [[WHO: Immunization data](#)] and the policy implications of the findings in the report overall, **we recognize that we should have provided additional information about and from the report as below.**

- The [IQVIA Institute for Human Data Science](#) “contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.” The Institute is a unit of IQVIA – “a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise...With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.”
- While the [Global Coalition on Aging](#) is mentioned as a collaborator and quoted in the media release, it is not mentioned in the report proper and no further information about its specific collaborative role was identified in our review.
- IQVIA clarifies that its modeling and the brief overall is based in part on its proprietary database IQVIA *MIDAS* – “a unique platform for assessing worldwide healthcare markets. It integrates IQVIA’s national audits into a globally consistent view of the pharmaceutical market, tracking virtually every product in hundreds of therapeutic classes, and provides estimated product volumes, trends and market share through retail and non-retail channels. MIDAS data is updated monthly and retains 12 years of history.”
- The research covered the following countries [panel from report]

This research covered the following countries:

Algeria	Finland	Malaysia	Serbia
Argentina	France	Mali	Slovakia
Australia	Gabon	Mexico	Slovenia
Austria	Germany	Morocco	South Africa
Belarus	Greece	Netherlands	Spain
Belgium	Guinea	New Zealand	Sweden
Benin	Hong Kong	Niger	Switzerland
Brazil	Hungary	Norway	Taiwan
Bulgaria	India	Pakistan	Thailand
Burkina Faso	Indonesia	Peru	Togo
Cameroon	Ireland	Philippines	Tunisia
Canada	Italy	Poland	Turkey
Chad	Ivory Coast	Portugal	UAE
Chile	Japan	Puerto Rico	UK
China	Jordan	Republic of Congo	Uruguay
Colombia	Korea	Romania	USA
Croatia	Kuwait	Russia	Vietnam
Czech	Latvia	Saudi Arabia	
Ecuador	Lebanon	Senegal	
Egypt	Luxembourg		

- A key finding in the report and its footnotes [p.2]:

**"Estimated Missed Doses ~100MN (RANGE: 80-119MN) DOSES ARE ESTIMATED TO HAVE BEEN MISSED IN 2021 AND 2022" –**


The trends in vaccine doses for adults prior to the COVID-19 vaccination have been utilized to model the expected doses if the positive developments in vaccine uptake had continued. This modelling exercise provides two scenarios (Exhibit 2):

Scenario 1: This scenario uses the historical data trendline for the pre-pandemic period (2013-19). This period had a CAGR of 7.9% and extends the trendline up to 2022. The trendline smooths variations in the overall historical trend for the selected period (2013–19). The difference between the projected trendline for 2021 and 2022 and actual doses is 24Mn doses in 2021 and 57Mn doses in 2022, giving a total of 81Mn estimated missed doses of adult vaccines (TDaP, herpes zoster, hepatitis B, influenza and pneumococcal).

Scenario 2: This scenario uses the historical data trend line for 2013 to 2020. This period had a CAGR of 8.9% and extends the trendline to 2022. The trendline smooths variations in the overall historical trend for the selected period (2013-20). The difference between the projected trendline and actual doses is 41Mn doses in 2021 and 77Mn doses in 2022, giving a total of 119Mn estimated missed doses of adult vaccines.

The mid-point of these two scenarios gives an estimated 100Mn missed doses for the two years.

Exhibit 2: Estimated adult vaccine missed doses in 2021 and 2022



Source: IQVIA MIDAS®, June 2023; CDC (Influenza Vaccination Coverage, Children 6 months through 17 years, United States); UK Government (Vaccination coverage for children and mothers).

Notes: Adult vaccinations includes influenza; diphtheria and tetanus (Td); diphtheria, tetanus and pertussis (TDaP); hepatitis B; herpes zoster and pneumococcal. Diphtheria, tetanus and pertussis vaccinations in combination with polio or hepatitis B are not included. A 75:25% adult:pediatric split for

influenza and 1/3:2/3 split for pneumococcal has been applied in accordance with available adult and pediatric coverage (UK and US). Only hepatitis B doses of 1mL or larger were assumed for adult use.

Scenario 1 and 2 are developed from trendlines from 2013 to 2019 or 2020, respectively. Includes retail and non-retail from 76 countries covered by IQVIA MIDAS panels. These may not cover all vaccination delivery channels in each country.

.....

#### *Media Release*

### **[New analysis shows lost ground on adult immunisation during the pandemic with 100 million doses potentially missed](#)**

- Despite successes in Covid-19 vaccination programmes, global uptake of some other adult vaccines fell during the same timeframe—compounding already low adoption of adult immunisation
- Data also show investment in adult vaccines remains low at less than 2% of total pharmaceutical expenditure in all regions
- The analysis provides new evidence on why changes are needed, given existing data that show adult vaccine-preventable diseases are a major cause of morbidity, mortality and healthcare cost

10 July 2023

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), **estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic...**

.....

.....

.....

## ***PHEIC*** **Polio**

### **[Polio this week as of 26 July 2023 - GPEI](#)**

#### *Headlines*

:: “While the challenges before us are formidable and complex, I remain cautiously optimistic about the goal of interrupting transmission of poliovirus in Pakistan by the end of this year. This will require solidarity and collective action at all levels to enable rigorous implementation of the strategy, that must be fully supported by communities and the political, administrative and security leadership,” – WHO Regional Director Dr Ahmed Al-Mandhari. [Read more...](#)

:: Health teams in Sudan are going to extraordinary levels of coordination to detect polio amidst the conflict. Part of this work includes sending stool samples of children presenting with acute flaccid paralysis, a symptom of polio, across states for testing to the Argeen point of entry with Egypt. [Read more...](#)

:: nOPV2 rollout: Approximately 700 million doses of nOPV2 have been administered across 31 countries under its WHO Emergency Use Listing (EUL) to date. An additional 14 countries have met the requirements for nOPV2 use in the event of an outbreak. More information on nOPV2 is available [here](#).

*Summary of new polioviruses this week:*

- Afghanistan: three WPV1 positive environmental samples
- Algeria: one cVDPV2 positive environmental sample
- Burundi: one cVDPV2 positive environmental sample
- DR Congo: one cVDPV2 case
- Nigeria: two cVDPV2 cases and three cVDPV2 positive environmental samples



**Coronavirus [COVID-19]**

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

***WHO Weekly Epidemiological and Operational updates***

*Last update: 26 July 2023*

**Confirmed cases ::** 768 560 727

**Confirmed deaths ::** 6 952 522

**Vaccine doses administered:** 13 490 832 730

**[Weekly epidemiological update on COVID-19 - 27 July 2023](#)**

*Overview*

Globally, over 868 000 new COVID-19 cases and over 3700 deaths were reported in the last 28 days (26 June to 23 July 2023). While five WHO regions have reported decreases in the number of both cases and deaths, the Western Pacific Region has reported an increase in the number of both cases and deaths. As of 23 July 2023, over 768 million confirmed cases and over 6.9 million deaths have been reported globally. Currently, reported cases do not accurately represent infection rates due to the reduction in testing and reporting globally. During this 28-day period, 52% (122 of 234) of countries and territories reported at least one case – a proportion that has been declining since mid-2022.



***Our World in Data***

**[Coronavirus \(COVID-19\) Vaccinations](#)** [Accessed 29 Jul 2023]

:: [70.5%](#) of the world population has received at least one dose of a COVID-19 vaccine.

:: [13.49 billion doses](#) have been administered globally, and [155,445](#) are now administered each day.

:: [32.4%](#) of people in low-income countries have received at least one dose.



**MPOX**

<https://www.who.int/emergencies/situation-reports>

*Last Report:*

**[Multi-country outbreak of mpox, External situation report #26 – 14 July 2023](#)**





.....

## **UN OCHA – Current Emergencies**

*Current Corporate Emergencies*

### **Afghanistan**

**[Afghanistan: Humanitarian Update, June 2023](#)**

### **Northern Ethiopia**

**[Ethiopia - Situation Report, 27 Jul 2023](#)**

### **Somalia**

**[Somalia: 2023 Flash and Riverine Floods Situation Report No. 3 \(as of 13 July 2023\)](#)**

Posted 17 Jul 2023

### **Türkiye/Syria Earthquakes**

28 Jul 2023

**[Today's top news: Syria, Niger](#)**

### **Ukraine**

*Highlights* Last Updated: 26 May 2023

.....

.....

## ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....

.....

## **WHO & Regional Offices [to 29 Jul 2023]**

<https://www.who.int/news>

*Selected News/Announcements/Statements*

28 July 2023 Departmental news

### **[Vaccines could avert half a million deaths associated with anti-microbial resistance a year](#)**

Globally there are 4.95 million deaths per year associated with antimicrobial resistance (AMR). Low- and middle-income countries bear the burden of drug-resistant infections. AMR, which occurs when bacteria, virus, fungi and parasites change over time and no longer respond to existing treatments, was described by WHO in 2019 as one of the top ten global threats to public health – a threat to which science is playing catch-up in its efforts to mitigate.

A [new study](#) published in the BMJ Global Health has found that over half a million lives could be saved each year with the effective use of existing vaccines and the continued development of new vaccines to tackle priority pathogens. The study highlights the importance of preventive measures including vaccination in slowing and containing the spread of AMR.

The study was carried out by the World Health Organization (WHO), the International Vaccine Institute, Korea (IVI) and the London School of Hygiene & Tropical Medicine. The authors used data from 2019 to model the potential impact of 15 new and existing vaccines against pathogens in WHO's list of bacterial priority pathogens.

They found that if the vaccines are used for key populations, not only could half a million lives be saved, but 28 million disability-adjusted life-years (DALYs) would be averted, meaning the numbers of years lost to disability or reduced lifespans as a result of infection. In the scenario where seven of the vaccines were used for broader populations, an additional 1.2 million deaths and 37 million DALYs would be prevented...

26 July 2023 News release

[\*\*WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis\*\*](#)

25 July 2023 Departmental news

[\*\*Building Vaccine Manufacturing Excellence: Join The Fourth Virtual cGMP Training Marathon - Principles into Practice\*\*](#)

25 July 2023 News release

[\*\*Member States continue work on potential pandemic accord\*\*](#)

Member States of the World Health Organization (WHO) continued their discussions towards a global accord on pandemic prevention, preparedness and response, with a view to presenting the outcome of their work to the World Health Assembly in May 2024.

The Bureau's text of the WHO CA+ was discussed 17-21 July during the sixth meeting of the Intergovernmental Negotiating Body (INB) to draft and negotiate an international instrument to strengthen pandemic prevention, preparedness and response. This document was prepared by the Bureau of the INB following the fifth meeting of the INB based on all inputs provided by Member States, and it was distributed to all Member States and published on the WHO website in May/June 2023...

25 July 2023 Departmental news

[\*\*WHO to host first global workshop on biodiversity, traditional knowledge, health and well-being\*\*](#)

25 July 2023 Departmental news

[\*\*WHO issues rapid communication on use of targeted next-generation sequencing for diagnosis of drug-resistant tuberculosis\*\*](#)

24 July 2023 News release

[\*\*WHO releases new guidance to improve testing and diagnosis of sexually transmitted infections\*\*](#)

23 July 2023 News release

[\*\*New WHO guidance on HIV viral suppression and scientific updates released at IAS 2023\*\*](#)

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region**

**[Uganda elevates health for all with free hepatitis testing, treatment and vaccines](#)**

28 July 2023

**WHO Region of the Americas PAHO**

:: 28 Jul 2023

**[Increased use of diagnostics and medicines for viral hepatitis could save up to 100.000 lives in the Americas each year](#)**

The cost of treating hepatitis B and C has reduced dramatically the last 10 years, making hepatitis medicines an affordable way to control the disease and prevent deaths Washington, D.C., 27 July 2023 (PAHO) – On the eve of World Hepatitis Day, the Pan American Health Organization (PAHO) is urging countries to rapidly scale-up access to...

:: 26 Jul 2023

**[Questions and answers on avian influenza A\(H5N1\)](#)**

"The avian influenza epidemic poses a real threat to animals and a potential threat to humans." July 2023 (PAHO/WHO)—In January this year, the Pan American Health Organization (PAHO) warned about outbreaks of highly pathogenic avian influenza in birds in countries of the Americas. For the first time, a human case of avian influenza A (H5N1) was...

:: 25 Jul 2023

**[PAHO and Inter-American Development Bank celebrate 5-year collaboration on digital health in the Americas](#)**

Washington D.C. 25 July 2023 – At an event to celebrate five years of collaboration in information systems and digital health between the Pan American Health Organization (PAHO) and the Inter-American Development Bank (IBD), the PAHO Director, Dr. Jarbas Barbosa, underscored the crucial role of digital transformation in pandemic recovery and...

**WHO South-East Asia Region SEARO**

**[Bhutan, Timor-Leste eliminate rubella; Achieve 2023 target of measles and rubella elimination](#)**

21 July 2023 *News release* New Delhi

The World Health Organization South-East Asia Region today announced Bhutan and Timor-Leste have eliminated rubella, a highly contagious disease that causes serious illness and irreversible birth defects in newborns of women infected during pregnancy, but preventable through vaccination. Bhutan and Timor-Leste had eliminated measles in 2017 and 2018 respectively, and now join Maldives and Sri Lanka to achieve elimination of measles and rubella by 2023, a flagship priority program of WHO South-East Asia Region...

**WHO European Region EURO**

*No new digest content identified.*

**WHO Western Pacific Region**

*No new digest content identified.*

.....

**Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[\*\*28 July 2023 | Circulating vaccine-derived poliovirus type 2 \(cVDPV2\) - United Republic of Tanzania\*\*](#)

[\*\*28 July 2023 | Circulating vaccine-derived poliovirus type 2 \(cVDPV2\) - Kenya\*\*](#)

[\*\*25 July 2023 | Guillain-Barré Syndrome - Peru\*\*](#)

[\*\*24 July 2023 | Middle East Respiratory Syndrome - United Arab Emirates\*\*](#)

.....

### **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

26 July 2023

[\*\*The Big Catch-Up: An Essential Immunization Recovery Plan for 2023 and Beyond\*\*](#)

26 July 2023

[\*\*AWaRe classification of antibiotics for evaluation and monitoring of use, 2023\*\*](#)

26 July 2023

[\*\*WHO Model List of Essential Medicines for Children - 9th list, 2023\*\*](#)

26 July 2023

[\*\*WHO Model List of Essential Medicines - 23rd list, 2023\*\*](#)

26 July 2023

[\*\*The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert...\*\*](#)

25 July 2023

[\*\*Entomological manual for onchocerciasis elimination programmes\*\*](#)

24 July 2023

[\*\*Community experiences of the 2022–2023 mpox outbreak in Europe and the Americas\*\*](#)

24 July 2023

[\*\*Target product profile for a diagnostic test to confirm leprosy in individuals with clinical signs and...\*\*](#)

23 July 2023

[\*\*Use of targeted next-generation sequencing to detect drug-resistant tuberculosis\*\*](#)

22 July 2023

**[The role of HIV viral suppression in improving individual health and reducing transmission](#)**

.....

**USA – HHS, FDA, CDC**

**HHS**

*News*

*No new digest content identified.*

**FDA**

*Press Announcements*

**[FDA Roundup: July 28, 2023](#)**

... On Thursday, the FDA approved Ervebo, a vaccine for the prevention of Ebola virus disease caused by Zaire ebolavirus in individuals 12 months through 17 years of age. Ervebo has been approved for use in individuals 18 years of age and older since December 2019. Cases of Ebola are very rare in the U.S., and those that have occurred have been the result of infections acquired by individuals in other countries who then traveled to

**FDA VRBPAC**

*Advisory Committee Calendar*

*No new meetings identified.*

**CDC/ACIP [U.S.] [to 29 Jul 2023]**

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

*No new digest content identified.*

**ACIP Meetings**

*Next ACIP Meeting*

August 3, 2023 11:00am – 3:30pm EDT

[Agenda](#) [Webcast Link](#)

ACIP meetings are virtual. No registration is required to watch the webcasts.

**MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

July 28, 2023 / No.30

[PDF of this issue](#)

- [Travel-Associated Dengue Cases — United States, 2010–2021](#)
- [Demographic Disparities in Mpox Vaccination Series Completion, by Route of Vaccine Administration — California, August 9, 2022–March 31, 2023](#)
- [Notes from the Field: Cruise Ship Norovirus Outbreak Associated with Person-to-Person Transmission — United States Jurisdiction, January 2023](#)

- [QuickStats: Percentage of Adults Aged ≥18 Years who Received an Influenza Vaccination in the Past 12 Months, by Race and Ethnicity and Family Income — National Health Interview Survey, United States, 2021](#)

.....  
.....

## Europe

### European Medicines Agency [EMA]

[https://www.ema.europa.eu/en/search/search/ema\\_editorial\\_content/ema\\_news?sort=field\\_ema\\_computed\\_date\\_field&order=desc](https://www.ema.europa.eu/en/search/search/ema_editorial_content/ema_news?sort=field_ema_computed_date_field&order=desc)

*News & Press Releases*

#### [News: Paving the way towards coordinated clinical trials in public health emergencies in the EU \(new\)](#)

Last updated: 25/07/2023

.....

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports [Selected]*

#### [World Hepatitis Day 2023: need to scale up efforts to address hepatitis B and C](#)

Campaign - 28 Jul 2023

#### [Weekly COVID-19 country overview](#)

Epidemiological update - 27 Jul 2023

.....  
.....

### Africa CDC [to 29 Jul 2023]

<http://www.africacdc.org/>

*News*

*Statement*

#### [The Africa Centres for Disease Control and Prevention \(Africa CDC\) Statement on the Allocation of Funding in the First Call for Proposals by the Pandemic Fund](#)

27 July 2023

... Africa CDC commends the Pandemic Fund for the outcome of the first call for proposals with 19 Grants approved, which is praiseworthy given the gaps in meeting the initial commitment of 1.6 billion dollars pledged by donors at the Fund's launching. Africa CDC notes that only 9% of African countries (5 out of the 55 AU Member States) representing less than 5% of Africa's population will benefit from this first call of proposals. While congratulating the five countries and committing to support them for implementation, Africa CDC remains concerned about the limited impact of this first allocation on pandemic preparedness, prevention, and response (PPPR) in Africa due to its limited size and lack of regional approach.

Africa CDC notes that Africa is the only region without a regional proposal. In contrast, other regions adopted a regional approach to maximize the impact of the Pandemic Fund on their entire countries

and populations: Caribbean region with 12 countries, South America with 7 countries, and Central Asia with 5 countries. The considerable discrepancy stems from the Pandemic Fund's failure to acknowledge the vital role that Africa CDC could have played as an Implementing Entity for the Fund, considering its central role in supporting health initiatives across the continent.

Overlooking the inclusion of Africa CDC, which is the sole continental public health institution, was an unfortunate oversight. As a result, Africa's health security gaps remain inadequately addressed, leading to the absence of multi-country/regional proposals from the continent...

.....  
.....

### **China CDC**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China** [to 29 Jul 2023]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC** [to 29 Jul 2023]

<http://english.nmpa.gov.cn/>

*News*

#### **[China issues plan for mpox disease prevention, control](#)**

2023-07-28

Chinese health authorities have issued a plan for the prevention and control of mpox disease, the national administration of disease prevention and control announced on Thursday.

### **China CDC Weekly Reports: Current Volume (5)**

2023-07-28 / No. 30

[View PDF of this issue](#)

- [Vital Surveillances: Changes in HIV-1 Subtypes/Sub-Subtypes, and Transmitted Drug Resistance Among ART-Naïve HIV-Infected Individuals — China, 2004–2022](#)
- [Notes from the Field: No Novel Prevalent Mutations Detected in the Circulating Strains of BF.7, BA.5.2, DY, and XBB — China, November 2022 to June 2023](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, January 2023\\*](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, February 2023\\*](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, March 2023\\*](#)

.....  
.....

***Contents*** [\[click to move among sections\]](#)

:: [Milestones, Perspectives](#)

:: [WHO](#)  
:: [Organization Announcements](#)  
:: [Journal Watch](#)  
:: [Pre-Print Servers](#)

.....  
.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 29 Jul 2023]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 29 Jul 2023]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 29 Jul 2023]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 29 Jul 2023]

<https://carb-x.org/>

*News*

07.27.2023 |

**[GERMAN GOVERNMENT RENEWS COMMITMENT TO CARB-X](#)**

*Millions injected into antimicrobial resistance research and development*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 29 Jul 2023]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – July 2023](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – July 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment](#) -

19 July 2023 – Issue 05



**CEPI – Coalition for Epidemic Preparedness Innovations** [to 29 Jul 2023]

<http://cepi.net/>

*Latest News*

*No new digest content identified.*

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 29

Jul 2023]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 29 Jul 2023]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 29 Jul 2023]

<https://dukeghic.org/>

*Report*

*No new digest content identified.*

**EDCTP** [to 29 Jul 2023]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*No new digest content identified.*

**Emory Vaccine Center** [to 29 Jul 2023]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 29 Jul 2023]

<http://www.euvaccine.eu/>

*Latest News, Events*

*EVI*

**[TRANSAVC2 concludes: key achievements and new horizons](#)**

July 2023 The TRA

... Over the duration of the TRANSVAC2 project, spanning from April 1, 2017, to April 30, 2023, the primary focus was the establishment of an efficient and well-coordinated research and innovation environment dedicated to providing scientific and technical services to the vaccine research and development (R&D) community...

**Evidence Aid** [to 29 Jul 2023]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

**[Impact of disasters caused by natural hazards on non-communicable diseases](#)**

Added July 20, 2023

**[Nurse education and training for disasters](#)**

Added July 19, 2023

**[The seismic risks of open spaces in the built environment](#)**

Added July 18, 2023

**Fondation Merieux** [to 29 Jul 2023]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 29 Jul 2023]

<https://www.gavi.org/>

*News Releases*

28 July 2023

**[New funding boosts efforts to vaccinate "zero-dose" children in the Democratic Republic of the Congo](#)**

:: DRC will receive US\$ 59.7 million through Gavi's Equity Accelerator Fund to help reduce the number of zero-dose children – who receive no basic vaccines – by 35% by 2025

:: The funding, which builds on the Mashako Plan 2.0 and the Kinshasa Declaration, will support activities including tracking vaccinations using GPS and SMS, identifying zero-dose children with community healthcare workers, door-to-door outreach, and tackling gender-related obstacles that impact demand across new priority areas

**GHIT Fund** [to 29 Jul 2023]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 29 Jul 2023]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 29 Jul 2023]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 29 Jul 2023]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 29 Jul 2023]

<https://www.hhmi.org/news>

*Press Room*

*Science Education* Jul 27 2023

**[HHMI Awards 50 New Gilliam Fellowships to Advance Equity and Inclusion in Science](#)**

Fifty graduate students and their advisers join the thriving community supported by the HHMI Gilliam Fellows Program.

**Human Vaccines Project** [to 29 Jul 2023]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 29 Jul 2023]

<https://www.iavi.org/>

*Latest News*

*No new digest content identified.*

**INSERM** [to 29 Jul 2023]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 29 Jul 2023]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

**Public Consultation: ICH E6(R3) Principles, Annex 1 and Annex 2**

The E6(R3) EWG is working on the revision of the E6(R2) Guideline "Good Clinical Practice" (GCP) with a view to addressing the application of GCP principles to the increasingly diverse trial types and data sources being employed to support regulatory and healthcare related decision-making on drugs, and provide flexibility whenever appropriate to facilitate the use of technological innovations in clinical trials. Additional information may also be found in ICH Reflection Paper on "GCP Renovation" on the [ICH Reflection Paper page](#). When complete, E6(R3) will be composed of an overarching principles and objectives document, Annex 1 and Annex 2.

**E6(R3) Draft Guideline**

*Public consultation dates:*

FDA, USA – Comment period ends 05 September 2023

ANVISA, Brazil - Deadline for comments by 31 August 2023

EC, Europe - Deadline for comments by 26 September 2023

MHRA, UK - Deadline for comments by 31 August 2023

TFDA, Chinese Taipei - Deadline for comments by 31 August 2023

**ICRC** [to 29 Jul 2023]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

**Bangladesh: Over 227,000 patients received life-saving medical assistance thanks to the Kuwait Red Crescent Society's support**

Thanks to this agreement, the ICRC, along with its Bangladesh Red Crescent Society partners, contributed to the growth of the Emergency Department, while increasing the skillset of its medical professionals.

24-07-2023 | News release

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 29 Jul 2023]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*No new digest content identified.*

**Institut Pasteur** [to 29 Jul 2023]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 29 Jul 2023]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Blogs*

**[Global science needs a new approach to tackle climate change and complex sustainability question](#)**

27.07.2023

*Blogs*

**[The ISC addresses the UN High Level Political Forum and meets with the UN Secretary General](#)**

24.07.2023

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 29 Jul 2023]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

**[As Immunization Coverage Begins to Recover, Inequities Remain](#)**

July 2023

Although we are beginning to recover from the immunization backslide caused by the COVID-19 pandemic, the recently released WHO and UNICEF national estimates of immunization coverage (WUENIC) shows that continued efforts are needed to ensure equitable access to vaccines. These life-saving vaccines are critical to prevent unnecessary illnesses and deaths and to provide a higher [...]

**IVI** [to 29 Jul 2023]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 29 Jul 2023]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News [Selected]*

**Johns Hopkins Center for Health Security co-hosts India–United States Strategic Dialogue to discuss critical biosecurity issues**

July 26, 2023

**MSF/Médecins Sans Frontières** [to 29 Jul 2023]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Conflict in Sudan*

**Hundreds of thousands face disease in overcrowded camps in White Nile state**

Project Update 27 Jul 2023

**National Academy of Medicine** - USA [to 29 Jul 2023]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 29 Jul 2023]

<https://www.nationalacademies.org/newsroom?>

*News*

**U.S. Should Create a Federal Entity Responsible for Advancing Racial, Ethnic, and Tribal Health Equity, and Implement a Health Equity Policy Audit and Score Card**

The U.S. should create a federal entity responsible for advancing racial, ethnic, and tribal health equity, implement an equity audit of current agency policies, and design a score card to assess how proposed legislation might impact health equity.

Date: 2023-07-27

Type: News Release

**National Vaccine Program Office** - U.S. HHS [to 29 Jul 2023]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

**September 21-22, 2023 NVAC Meeting**

**NIH** [to 29 Jul 2023]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**PATH** [to 29 Jul 2023]

<https://www.path.org/media-center/>

*Press Releases*

**PATH releases Diversity, Equity, and Inclusion 2025 Strategy**

Published: July 2023 *Announcement*

**Rockefeller Foundation** [to 29 Jul 2023]

<https://www.rockefellerfoundation.org/>

*Selected Reports/Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 29 Jul 2023]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 29 Jul 2023]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

*No new digest content identified.*

**UNICEF** [to 29 Jul 2023]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Press release 27 July 2023*

**[1 in 2 children in Europe and Central Asia are exposed to high heatwave frequency, double the global average](https://www.unicef.org/press-releases/1-2-children-europe-and-central-asia-are-exposed-high-heatwave-frequency-double)**

<https://www.unicef.org/press-releases/1-2-children-europe-and-central-asia-are-exposed-high-heatwave-frequency-double>

GENEVA, 27 July 2023 – Around half of children in Europe and Central Asia – or 92 million – are exposed to high heatwave frequency, according to an analysis of the latest available data from 50 countries published today by UNICEF in a new policy brief. This is double the global average of 1 in 4 children exposed to high heatwave frequency. Beat...

*Press release 24 July 2023*

**[Severe violations of children's rights an 'hourly occurrence' in Sudan, warns UNICEF](https://www.unicef.org/press-releases/severe-violations-childrens-rights-hourly-occurrence-sudan-warns-unicef)**

<https://www.unicef.org/press-releases/severe-violations-childrens-rights-hourly-occurrence-sudan-warns-unicef>

PORT SUDAN/NEW YORK, 24 July 2023 – As the brutal conflict in Sudan hits 100 days, UNICEF has received reports of a staggering 2,500 severe violations of children's rights —an average of at least one an hour. As these are just the numbers reported to UNICEF sources, the true figure is likely to be far higher, and a grim reminder of the day-to-day...

*Press release 23 July 2023*

**[UNICEF: Against the odds, children begin the new school year in Rohingya refugee camps](https://www.unicef.org/press-releases/unicef-against-odds-children-begin-new-school-year-rohingya-refugee-camps)**

<https://www.unicef.org/press-releases/unicef-against-odds-children-begin-new-school-year-rohingya-refugee-camps>

COX'S BAZAR, Bangladesh, 23 July 2023 – Against the odds of displacement, fires burning down learning centres, and Cyclone Mocha's wrath, classrooms in the Rohingya refugee camps in Bangladesh

are filling up today with children, excited on the first day of school. Thanks to expanded education opportunities for teenagers and girls,

**Unitaid** [to 29 Jul 2023]

<https://unitaid.org/>

*Featured News*

27 July 2023

[\*\*World Hepatitis Day: Unitaid is pioneering urgent solutions to tackle hepatitis C\*\*](#)

**Vaccine Equity Cooperative [nee Initiative]** [to 29 Jul 2023]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 29 Jul 2023]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 29 Jul 2023]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 29 Jul 2023]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

[\*\*Vaccine Update for Providers\*\*](#)

*July 2023*

**Wellcome Trust** [to 29 Jul 2023]

<https://wellcome.ac.uk/news>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 29 Jul 2023]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*Press Release Jul. 26, 2023*

[\*\*Wistar-Led Team Awarded More Than \\$12 Million Grant from the NCI to Investigate Link Between Epstein-Barr Virus and Carcinomas\*\*](#)



PHILADELPHIA — (JULY 26, 2023) — It's been known since the 1960s that Epstein-Barr Virus (EBV) causes a variety of cancers, but research has overwhelmingly focused on its connection to lymphomas.

**WFPHA: World Federation of Public Health Associations** [to 29 Jul 2023]

<https://www.wfpha.org/>

*Latest News - Blog*

**[The Alliance of Public Health Associations of the Americas: New Board Members](#)**

Jul 25, 2023

The Alliance of Public Health Associations of the Americas: New Board Members WFPHA congratulates the new elected board members of the Alliance of the Public Health Associations of the Americas (AASPA), Anulfo Lopez as President, Rosana Onocko as...

**[World Medical Association \[WMA\]](#)** [to 29 Jul 2023]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health** [to 29 Jul 2023]

<https://www.oie.int/en/>

*Press Releases, Statements*

*Selected Press Releases*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 29 Jul 2023]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 29 Jul 2023]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 29 Jul 2023]

<http://www.dcvmn.org/>

*News; Upcoming events*

**[24th DCVMN Annual General Meeting 2023](#)**

September 19 - 21, 2023

Cape Town, South Africa

**ICBA – International Council of Biotechnology Associations** [to 29 Jul 2023]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 29 Jul 2023]

<https://ifpma.org/>

*Selected Press Releases/Statement*

*Statement 24 Jul 2023*

**Fourth meeting of the Working Group on Amendments to the International Health Regulations**

On 24 July, IFPMA made a statement at the fourth meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva.

... With pragmatism as the cornerstone, we need to focus on preserving what works well – such as the innovation ecosystem – and removing barriers that are impacting our collective abilities to respond to public health risks. Looking to the future, early access to pathogens, open borders without upstream or downstream trade restrictions, and a strong IP incentive framework are what is needed.

In line with its technical scope, we encourage the WGIHR to consider:

- Ensuring and promoting the sharing of outbreak information, including the immediate and unhindered access to pathogens, as a critical step to help inform a coordinated global response to outbreaks and trigger R&D
- Delineating equitable access discussions under the WHO CA+...

*Statement 24 Jul 2023*

**Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) and the Working Group on Amendments to the International Health Regulations: Agenda item 3**

On 24 July, IFPMA delivered a statement for agenda item 3 at the “Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response and the Working Group on Amendments to the International Health Regulations (WGIHR) (2005)” in Geneva.

... On the joint issue discussed at IHR and INB related to access to pathogens and equitable access to pandemic countermeasures, we are concerned to see the Pandemic Influenza Preparedness (PIP) model used as a reference for developing solutions as we consider it unfit to ensure better pandemic preparedness and response, and not practically replicable beyond influenza for the following reasons:

1. There is a well-established, centralized tracking and sharing of influenza pathogens. For all other pathogens, sharing occurs through various networks, as well as bilaterally. Bringing all under the umbrella of WHO would be technically and legally challenging and would undermine the efforts of already established networks.
2. There are only a handful of influenza manufacturers, making it possible to sign Standard Material Transfer Agreements (SMTA2s) in inter-pandemic periods. Identifying who will be the successful innovators in the next pandemic is not possible. Applying the PIP model would imply signing SMTA2s with hundreds, possibly thousands of entities involved in vaccine, therapeutic, and diagnostic R&D related to pathogens of pandemic potential. You have to bear in mind that, over the last decade, only 14 SMTA2s were successfully signed.
3. The PIP model does not provide an obligation to share pathogens and does not solve the issue of burdensome national access- and benefit-sharing laws being applied to influenza samples, where

we have already seen cases of national ABS rules negatively impacting supplies of seasonal influenza vaccines.

4. An SMTA does not address export restrictions, which were a key barrier to equitable access during COVID-19, and hence might prevent companies' ability to comply with supply obligations.
5. Finally, PIP has fortunately never been used and tested since its creation and remains a theoretical model.

### **International Alliance of Patients' Organizations – IAPO** [to 29 Jul 2023]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

*No new digest announcements identified*

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

#### **[Global regulators and biopharmaceutical and vaccine industry to share experiences with managing pharmaceutical quality systems \(July 2023\)](#)**

On 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to pharmaceutical quality amongst national regulatory authorities worldwide.

### **PhRMA** [to 29 Jul 2023]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified*

.....  
.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

#### **AstraZeneca**

*Press Releases*

#### **[AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D](#)**

28 July 2023

#### **[Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies](#)**

28 July 2023

- Agreement furthers Alexion's ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas

**Bharat Biotech**

Press Releases - No new digest announcements identified

**BioCubaFarma** – Cuba

Ultimas Noticias - Website not responding at inquiry

**Biological E**

News - No new digest announcements identified

**BioNTech**

Press Releases - No new digest announcements identified

**Boehringer**

Press Releases - No new digest announcements identified

**CanSinoBIO**

News - Website not responding at inquiry

**CIGB**

Latest News

**[IV International Symposium Cancer 2023](#)**

Varadero, Cuba, September, 2023

**Cinnagen**

Recent News - No new digest announcements identified

**Clover Biopharmaceuticals** - China

News - No new digest announcements identified

**Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

**Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

**GSK**

Press releases for media

24 July 2023

**[ViiV Healthcare's cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency](#)**

Cabotegravir is the first and only long-acting injectable option for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1

**IMBCAMS**, China

Home - Website not responding at inquiry

**Janssen/JNJ**

Press Releases

Jul 28, 2023 *United States*

**[Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT®](#)**

**Merck**

News releases

July 27, 2023

**[Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials](#)**

July 26, 2023

**[Merck and Moderna Initiate Phase 3 Study Evaluating V940 \(mRNA-4157\) in Combination with KEYTRUDA® \(pembrolizumab\) for Adjuvant Treatment of Patients with Resected High-Risk\(Stage IIB-IV\) Melanoma](#)**

**Moderna**

Press Releases

26 July, 2023

**[Merck and Moderna Initiate Phase 3 Study Evaluating V940 \(mRNA-4157\) in Combination with KEYTRUDA® \(pembrolizumab\) for Adjuvant Treatment of Patients with Resected High-Risk \(Stage IIB-IV\) Melanoma](#)**

**Nanogen**

News - *No new digest announcements identified*

**Novartis**

News - *No new digest announcements identified*

**Novavax**

Press Releases - *No new digest announcements identified*

**Pfizer**

Recent Press Releases

07.27.2023

**[Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy](#)**

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.

Effective today, Chris Boshoff, M.D., PhD, will join Pfizer's Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and Chief Executive Officer, Albert Bourla...

**R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

## **Sanofi Pasteur**

[Press Releases](#) - No new digest announcements identified

## **Serum Institute of India**

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

## **Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified

## **Sinovac**

[Press Releases](#)

2023/07/28 | [Press Releases](#)

[SINOVAC Expands Strategic Partnership with Bio Farma, Bolstering Indonesia's Vaccine Supply](#)

## **SK Biosciences**

[Press Releases](#) - No new digest announcements identified

## **Takeda**

[Newsroom](#) - No new digest announcements identified

## **Valneva**

[Press Releases](#) - No new digest announcements identified

## **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - Website not responding [404 error]

## **WestVac Biopharma**

[Media](#) - No new digest announcements identified

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

*Article*

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 25, Number 7: E467-572

<https://journalofethics.ama-assn.org/issue/how-we-over-rely-bmi>

#### ***How We Over Rely on BMI***

Patients who are fat or perceived as fat are commonly characterized by some clinicians as unreliable narrators of their own health histories. Negative bias can undermine diagnoses, intervention decisions, and even what some clinicians think fat patients deserve. Fat is widely considered a clinical threat, and obesity is a descriptor applied to patients with BMIs at or over 30. While weight and BMI can be helpful clinical indicators, many of its applications are overvalued, imprecise, contested, and can incur substantial iatrogenic harm. This theme issue examines clinical and ethical shortcomings of medicine's current approaches to fat.

### **American Journal of Infection Control**

July 2023 Volume 51 Issue 7 p725-846

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

July 2023 Volume 65 Issue 1 p1-172

[Reviewed earlier]

### **American Journal of Public Health**

August 2023 113(8)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 109 (2023): Issue 1 (Jul 2023)  
<https://www.ajtmh.org/view/journals/tpmd/109/1/tpmd.109.issue-1.xml>  
[Reviewed earlier]

### **Annals of Internal Medicine**

July 2023 Volume 176, Issue 7  
<https://www.acpjournals.org/toc/aim/current>  
*Original Research*

#### **[Clinical Characteristics and Outcomes Among Travelers With Severe Dengue A GeoSentinel Analysis](#)**

Ralph Huits, MD, PhD, Kristina M. Angelo, DO, Bhawana Amatya, MD, Sapha Barkati, MD, MSc, ... et al.  
Pages:940–948

#### **[Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV](#)**

Monica Gandhi, MD, MPH, Matthew Hickey, MD, Elizabeth Imbert, MD, Janet Grochowski, PharmD, ... et al.  
Pages:969–974

#### **[Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection - A Prospective Cohort Study](#)**

Apurv Soni, MD, PhD, Carly Herbert, BA, Honghuang Lin, PhD, Yi Yan, PhD, Caitlin Pretz, MS, ... et al.  
Pages:975–982

### *Special Articles*

#### **[COVID-19 Is No Longer a Public Health Emergency: Implications for Patients and Clinicians](#)**

FREE  
Christine Laine, MD, MPH and Darilyn V. Moyer, MD  
Pages:983–984

### **Artificial Intelligence – An International Journal**

Volume 320 July 2023  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/320/suppl/C>  
[New issue; No digest content identified]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 29 Jul 2023)  
[No new digest content identified]

### **BMJ Global Health**

July 2023 - Volume 8 - 7  
<https://gh.bmj.com/content/8/7>



[Reviewed earlier]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 Jul 2023)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 Jul 2023)

#### **[Prevalence of tuberculosis and associated factors among presumptive TB refugees residing in refugee camps in Ethiopia](#)**

*Tuberculosis (TB) causes significant morbidity and mortality in refugee populations. Although Ethiopia is the third largest refugee-hosting country in Africa, there is limited published data on the prevalence*

...

Authors: Abyot Meaza, Bazezew Yenew, Miskir Amare, Ayinalem Alemu, Michael Hailu, Dinka Fikadu Gamtesa, Mirgissa Kaba, Girmay Medhin, Gobena Ameni and Balako Gumi

Citation: BMC Infectious Diseases 2023 23:498

Content type: Research Published on: 28 July 2023

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 Jul 2023)

#### **[Communication of patients' and family members' ethical concerns to their healthcare providers](#)**

*Little is known about communication between patients, families, and healthcare providers regarding ethical concerns that patients and families experience in the course of illness and medical care. To address t...*

Authors: Mariam Noorulhuda, Christine Grady, Paul Wakim, Talia Bernhard, Hae Lin Cho and Marion Danis

Citation: BMC Medical Ethics 2023 24:56

Content type: Research Published on: 29 July 2023

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 Jul 2023)

#### **[Estimating the full health and economic benefits of current and future influenza vaccines](#)**

Authors: K. E. Lafond, R. Gharpure, V. G. Dugan and E. Azziz-Baumgartner

Citation: BMC Medicine 2023 21:273

Content type: Correspondence Published on: 27 July 2023

#### *Abstract*

In the dynamic landscape of respiratory virus vaccines, it is crucial to assess the value of novel mRNA and combination influenza/COVID-19 vaccines in low- and middle-income countries. Modeling studies, such as the one conducted by Waterlow et al., provide vital information about the cost–benefit

potential of these products compared to currently licensed vaccines. However, this approach only accounts for directly measured medically attended influenza-associated illnesses and has two major limitations. First, this method fails to capture the full disease burden of influenza (including non-respiratory and non-medically attended influenza illnesses), which are particularly important drivers of disease burden in infants and older adults. Second, the model does not describe the ancillary benefits of influenza vaccination such as the attenuation of severe disease, prevention of severe non-respiratory outcomes (e.g., myocardial infarctions), or reduced antibiotic use. To obtain a comprehensive understanding of the benefits of influenza vaccines, we must strive to improve the inputs for future modeling-based evaluations.

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 Jul 2023)

#### **[COVID-19 vaccine registry for pregnant women: policy to control complications of vaccination in pregnant women in 2021–2022](#)**

*Data management related to COVID-19 vaccination in pregnant women is vital to improve the treatment process and to establish preventive programs. Implementing a registry to manage data is an essential part of ...*

Authors: Farkhondeh Asadi, Roya Shakiba, Reza Rabiei, Hassan Emami and Azam Sabahi

Citation: BMC Pregnancy and Childbirth 2023 23:542

Content type: Research Published on: 27 July 2023

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 Jul 2023)

#### **[Migration and health research: past, present, and future](#)**

*Global migration continues to rise at unprecedented rates. Migrants are an extremely heterogeneous group and face diverse health needs related to infectious diseases, sexual and reproductive health, non-communicable...*

Authors: Shira M Goldenberg and Florian Fischer

Citation: BMC Public Health 2023 23:1425

Content type: Editorial Published on: 25 July 2023

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 29 Jul 2023)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

August 2023 - Volume 28 - 4

<https://ebm.bmj.com/content/28/4>

[New issue; No digest content identified]

**BMJ Open**

May 2023 - Volume 13 - 5

<https://bmjopen.bmj.com/content/13/1>

[Reviewed earlier]

**Bulletin of the Atomic Scientists**

July 2023

<https://thebulletin.org/magazine/2023-07/>

***Special Issue: Oppenheimer***

Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 101(7); 2023 Jul 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/439294/>

[Reviewed earlier]

**Cell**

Jul 06, 2023 Volume 186 Issue 14 p2951-3136

<https://www.cell.com/cell/current>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 49, Issue 4 Pages: 617-785 July 2023

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 114, Issue 1 Pages: 1-238 July 2023

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

**Clinical Therapeutics**

June 2023 Volume 45 Issue 6 p483-616

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 20 Issue 4, August 2023

<https://journals.sagepub.com/toc/ctja/20/4>

*Articles*

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 29 Jul 2023]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 130 July 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/130/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 6, Issue 3 / June 2023

<https://www.liebertpub.com/toc/crispr/6/3>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 10, issue 3, September 2022

<https://link.springer.com/journal/40142/volumes-and-issues/10-3>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 39, Issue 7 2023

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

August 2023 - Volume 36 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

*INFECTIONS OF THE IMMUNOCOMPROMISED HOST*

[\*\*Machine learning and artificial intelligence for the diagnosis of infectious diseases in immunocompromised patients\*\*](#)

Tran, Nam K; Kretsch, Cileah; LaValley, Clayton; More

Current Opinion in Infectious Diseases. 36(4):235-242, August 2023.

*NOSOCOMIAL AND HEALTHCARE RELATED INFECTIONS*

[\*\*Burden of influenza in the elderly: a narrative review\*\*](#)

Conrad, Anne; Valour, Florent; Vanhems, Philippe

Current Opinion in Infectious Diseases. 36(4):296-302, August 2023.

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 23, Issue 2 Pages: 89-195 June 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

***Special Issue: Reproductive Justice: Inequalities in the Global South***

[Reviewed earlier]

### **Development in Practice**

Volume 33, Issue 5, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Development Policy Review**

Volume 41, Issue 4 July 2023

<https://onlinelibrary.wiley.com/toc/14677679/current>

*Articles*

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 6 - December 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 47, Issue 3 Pages: 543-846 July 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/3>

*Papers*

**[Governance and the design of post-disaster policies: a comparative analysis from Latin America and the Caribbean](#)**

Marco Córdova, Jonathan Menoscal, Esteban Moreno Flores

Pages: 766-787

First Published: 02 September 2022

**[Gaps in humanitarian WASH response: perspectives from people affected by crises, practitioners, global responders, and the literature](#)**

Travis Yates, Andy Bastable, John Allen, Cecilie Hestbæk, Bushra Hasan, Paul Hutchings, Monica Ramos, Tula Ngasala, Daniele Lantagne

Pages: 830-846

First Published: 22 November 2022

### **EMBO Reports**

Volume 24 Issue 7 5 July 2023

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 29, Number 6—June 2023

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 43 June 2023

<https://www.sciencedirect.com/journal/epidemics/vol/43/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 151 - 2023

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 45, Issue 4 Pages: 1-39 July–August 2023

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Trust and HIV-transmission trials :: Translational science and public input***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 37 - Issue 1 - Spring 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 28 June 2023

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/28/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 33, Issue 3, June 2023

<https://academic.oup.com/eurpub/issue/33/3>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 22 (1) 2023 *Issue In Progress*

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

May/June 2023 Volume 102, Number 3

<https://www.foreignaffairs.com/issues/2023/102/3>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 50, 2023 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 25, Issue 7 July 2023

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/7>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 Jul 2023]

[No new digest content identified]

### **Global Health Action**

Volume 16, Issue 1 (2023)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 3 June 21, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 29 Jul 2023]

[No new digest content identified]

### **Global Public Health**

Volume 18, Issue 1 (2023)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 29 Jul 2023]

[No new digest content identified]

### **Health and Human Rights**

Volume 25, Issue 1, June 2023,

<https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/>

#### ***Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks***

...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

### **Health Economics, Policy and Law**

Volume 18 - Issue 3 - July 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 38, Issue 5, June 2023

<https://academic.oup.com/heapol/issue/38/5>

[Reviewed earlier]

### **Health Research Policy and Systems**



<http://www.health-policy-systems.com/content>  
[Accessed 29 Jul 2023]  
[No new digest content identified]

### **Human Gene Therapy**

Volume 34, Issue 13-14 / July 2023  
<https://www.liebertpub.com/toc/hum/34/14-12>  
[New issue; No digest content identified]

### **Humanitarian Practice Network**

<https://odihpn.org/>  
*Featured Publications*  
[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 18, Issue 5, 2022  
<https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList>  
[Reviewed earlier]

### **Immunity**

Jul 11, 2023 Volume 56 Issue 7 p1429-1698  
<https://www.cell.com/immunity/current>  
[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>  
[Accessed 29 Jul 2023]  
[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>  
[Accessed 29 Jul 2023]  
[No new digest content identified]

### **International Health**

Volume 15, Issue 4, July 2023  
<https://academic.oup.com/inthealth/issue/15/4>  
[Reviewed earlier]

### **International Human Rights Law Review**

Volume 11 (2022): Issue 2 (Dec 2022)  
<https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml>  
*Table of Contents*  
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**  
Vol. 10 No. 7 (2023): July 2023  
<https://www.ijcmph.com/index.php/ijcmph/issue/view/102>  
[Reviewed earlier]

**International Journal of Epidemiology**  
Volume 52, Issue 3, June 2023  
<https://academic.oup.com/ije/issue>  
[Reviewed earlier]

**International Journal of Human Rights in Healthcare**  
Volume 16 Issue 3 2023  
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>  
*Table of contents*  
[Reviewed earlier]

**JAMA**  
July 25, 2023, Vol 330, No. 4, Pages 295-386  
<https://jamanetwork.com/journals/jama/currentissue>  
*Editorial*  
[\*\*Translating Clinical Trial Results to Clinical Practice During a Pandemic\*\*](#)  
Andre C. Kalil, MD, MPH; Angela Huttner, MD; Carlos A. Gomez, MD

**JAMA Health Forum**  
July 2023, Vol 4, No. 7  
<https://jamanetwork.com/journals/jama-health-forum/issue>  
[Reviewed earlier]

**JAMA Pediatrics**  
July 2023, Vol 177, No. 7, Pages 655-742  
<https://jamanetwork.com/journals/jamapediatrics/currentissue>  
[Reviewed earlier]

**JBI Evidence Synthesis**  
July 2023 - Volume 21 - Issue 7  
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

July 2023 Volume 73 Issue 1 p1-212

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 77 (2023)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

**Journal of Community Health**

Volume 48, issue 4, August 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-4>

**[Integrating HPV Vaccination Within PrEP care Delivery for Underserved Populations: A Mixed Methods Feasibility Study](#)**

Authors (first, second and last of 5)

Christopher W. Wheldon

Kevin J. Sykes

Bradley N. Collins

Content type: Original Paper

Published: 10 March 2023

Pages: 640 - 651

**[Parent-reported Barriers and Parental Beliefs Associated with Intentions to Obtain HPV Vaccination for Children in a Primary care Patient Population in Minnesota, USA](#)**

Authors (first, second and last of 6)

Xuan Zhu

Robert M. Jacobson

Lila J. Finney Rutten

Content type: Original Paper

Published: 15 March 2023

Pages: 678 – 686

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

June 18, 2023 Vol 6, No 06 (2023)

<https://www.cmro.in/index.php/jcmro/issue/view/68>

[Reviewed earlier]

**Journal of Development Economics**

Volume 164 September 2023

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/164/suppl/C>

[New issue; No digest content identified]

**Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 3, July 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

June 2023 - Volume 77 - 6

<https://jech.bmj.com/content/77/4>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 16, Issue 2 Pages: 101-258 June 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

*ARTICLES*

[Reviewed earlier]

**Journal of Global Ethics**

Volume 19, Issue 1 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 34, Number 3, August 2023

<https://muse.jhu.edu/issue/50808>

*Table of Contents*

[New issue; No digest content identified]

**Journal of Immigrant and Minority Health**

Volume 25, issue 3, June 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-3>

*Contents*

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>  
[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 228, Issue 2, 15 July 2023

<https://academic.oup.com/jid/issue/228/2>  
[Reviewed earlier]

**Journal of International Development**

Volume 35, Issue 5 Pages: 669-960 July 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>  
[Reviewed earlier]

**Journal of Medical Ethics**

July 2023 - Volume 49 - 7

<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 1 (2023)

<https://institutionalrepository.aah.org/jpcrr/>  
[Reviewed earlier]

**The Journal of Pediatrics**

Volume 261, October 2023

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/261/suppl/C>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 29 Jul 2023]

[No new digest content identified]

**Journal of Public Health Management & Practice**

September/October 2023 - Volume 29 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 44, issue 2, June 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-2>

*Articles*

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

July 2023 Volume 20 Issue 204

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 30, Issue 4, May 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 97 • Number 7 • July 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Jul 29, 2023 Volume 402 Number 10399 p347-424

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

[A broader vision for women's health](#)

The Lancet

### **The Lancet Child & Adolescent Health**

Aug 2023 Volume 7 Number 8 p519-598

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Jul 2023 Volume 5 Number 7 e395-e476

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Aug 2023 Volume 11 Number 8 e1137-e1313

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Jul 2023 Volume 23 Number 7 p763-878, e227-e265  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

### **Lancet Public Health**

Jul 2023 Volume 8 Number 7 e473-e574  
<https://www.thelancet.com/journals/lanpub/issue/current>  
[Reviewed earlier]

### **Lancet Respiratory Medicine**

Jul 2023 Volume 11 Number 7 p577-662, e61-e72`  
<https://www.thelancet.com/journals/lanres/issue/current>  
[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 27, issue 8, August 2023  
<https://link.springer.com/journal/10995/volumes-and-issues/27-8>  
[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 43 Issue 5, July 2023  
<http://mdm.sagepub.com/content/current>  
[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*  
Volume 101, Issue 2 Pages: 249-635 June 2023  
<https://onlinelibrary.wiley.com/toc/14680009/current>  
[Reviewed earlier]

### **Molecular Therapy**

Jul 05, 2023 Volume 31 Issue 7 p1859-2298  
<https://www.cell.com/molecular-therapy/current>  
[Reviewed earlier]

### **Nature**

Volume 619 Issue 7971, 27 July 2023  
<https://www.nature.com/nature/volumes/619/issues/7971>  
*Editorial* 25 Jul 2023

## **[ChatGPT is a black box: how AI research can break it open](#)**

Despite their wide use, large language models are still mysterious. Revealing their true nature is urgent and important.

### **Nature Biotechnology**

Volume 41 Issue 7, July 2023

<https://www.nature.com/nbt/volumes/41/issues/7>

[Reviewed earlier]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 29 Jul 2023)

[No new digest content identified]

### **Nature Genetics**

Volume 55 Issue 7, July 2023

<https://www.nature.com/ng/volumes/55/issues/7>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 7 Issue 6, June 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/6>

[Reviewed earlier]

### **Nature Medicine**

Volume 29 Issue 7, July 2023

<https://www.nature.com/nm/volumes/29/issues/7>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 22 Issue 7, July 2023

<https://www.nature.com/nrd/volumes/22/issues/7>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 24 Issue 7, July 2023

<https://www.nature.com/nrg/volumes/24/issues/7>

[Reviewed earlier]

### **Nature Reviews Immunology**



Volume 23 Issue 7, July 2023  
<https://www.nature.com/nri/volumes/23/issues/7>  
[Reviewed earlier]

### **New England Journal of Medicine**

July 27, 2023 Vol. 389 No. 4  
<https://www.nejm.org/toc/nejm/medical-journal>  
*Review Article*

#### **[AI in Medicine: Artificial Intelligence in U.S. Health Care Delivery](#)**

N.R. Sahni and B. Carrus

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>  
[Accessed 29 Jul 2023]  
[No new digest content identified]

### **Pediatrics**

Volume 152, Issue 1 July 2023  
<https://publications.aap.org/pediatrics/issue/152/1>  
[Reviewed earlier]

### **PharmacoEconomics**

Volume 41, issue 7, July 2023  
<https://link.springer.com/journal/40273/volumes-and-issues/41-7>  
[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>  
(Accessed 29 Jul 2023)  
[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 29 Jul 2023)  
[No new digest content identified]

### **PLOS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)  
(Accessed 29 Jul 2023)  
[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 29 Jul 2023)

#### **[Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study](#)**

Xi Xiong, David Tak Wai Lui, Matthew Shing Hin Chung, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Eric Yuk Fai Wan, Celine Sze Ling Chui, Xue Li, Franco Wing Tak Cheng, Ching-Lung Cheung, Esther Wai Yin Chan, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong, Ian Chi Kei Wong  
Research Article | published 24 Jul 2023 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004274>

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 29 Jul 2023)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 29 Jul 2023]

#### **[Prevalence and predictors of COVID-19 vaccination hesitancy among healthcare workers in Sub-Saharan Africa: A systematic review and meta-analysis](#)**

Eustes Kigongo, Amir Kabunga, Raymond Tumwesigye, Marvin Musinguzi, Ronald Izaruku, Walter Acup  
Research Article | published 28 Jul 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0289295>

#### **[Caregivers' perception and acceptance of malaria vaccine for Children](#)**

Victoria Bam, Abdulai Mohammed, Abigail Kusi-Amponsah, Jerry Armah, Alberta Yemotsoo Lomotey, Hayford Isaac Budu, Collins Atta Poku, Joana Kyei-Dompim, Catherine Dwumfour  
Research Article | published 26 Jul 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0288686>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 29 Jul 2023]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

July 11, 2023 | vol. 120 | no. 28

<https://www.pnas.org/toc/pnas/120/28>

[New issue; No digest content identified]

**PNAS Nexus**

Volume 2, Issue 6 June 2023

<https://academic.oup.com/pnasnexus/issue>

[Reviewed earlier]

**Prehospital & Disaster Medicine**

Volume 38 - Issue 3 - June 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 172 July 2023

<https://www.sciencedirect.com/journal/preventive-medicine/vol/172/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

12 July 2023 Volume 290 Issue 2002

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

**Public Health**

Volume 220 Pages 1-196 (July 2023)

<https://www.sciencedirect.com/journal/public-health/vol/220/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 16, Issue 1, April 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 138 Issue 4, July/August 2023

<https://journals.sagepub.com/toc/phrg/138/4>

[Reviewed earlier]

**Qualitative Health Research**

Volume 33 Issue 8-9, July 2023

<https://journals.sagepub.com/toc/qhra/current>

[New issue; No digest content identified]

## **Research Ethics**

Volume 19 Issue 3, July 2023

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 29 Jul 2023]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

24 Jul 2023

[\*\*READ-ing antimicrobial stewardship in the Caribbean: a tri-nation document review\*\*](#)

Original research | English |

24 Jul 2023

[\*\*Elimination of cervical cancer in Latin America \(Project ECHO-ELA\): lessons from phase one of implementation\*\*](#)

Original research | English |

24 Jul 2023

[\*\*COVID-19 mortality in metropolitan areas and other regions of Brazil, 2020 to 2021\*\*](#)

Original research | Portuguese |

## **Risk Analysis**

Volume 43, Issue 7 Pages: 1297-1519 July 2023

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 29 Jul 2023]

[No new digest content identified]

## **Science**

Volume 381| Issue 6656| 28 Jul 2023

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

### **Science and Engineering Ethics**

Volume 29, issue 3, June 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-3>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 15| Issue 706| 26 Jul 2023

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 29 Jul 2023]

[No new digest content identified]

### **Social Science & Medicine**

Volume 328 July 2023

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/328/suppl/C>

Research article Open access

[\*\*Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: Lessons for improving health and social equity\*\*](#)

Si Ying Tan, Chuan De Foo, Monica Verma, Piya Hanvoravongchai, ... Helena Legido-Quigley

Article 116007

*Research article Abstract only*

[\*\*The impact of the COVID-19 pandemic on inequalities in preventive health screenings: Trends and implications for U.S. population health\*\*](#)

Sneha Sarah Mani, Rebecca Anna Schut

Article 116003

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 29 Jul 2023]

[Reviewed earlier]

### **Theoretical Medicine and Bioethics**

Volume 44, issue 3, June 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-3>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 53 May–June 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/53/suppl/C>  
[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 28, Issue 7 Pages: i-iv, 507-585 July 2023  
<https://onlinelibrary.wiley.com/toc/13653156/current>  
[Reviewed earlier]

### **Vaccine**

Volume 41, Issue 27 Pages 3947-4064 (19 June 2023)  
<https://www.sciencedirect.com/journal/vaccine/vol/41/issue/27>

*Selected Content*

Article(s) from the Special Issue on "Latest developments in vaccine research: The 16th Vaccine Congress"; Edited by Dior Beerens and Gregory Poland

*Research article Abstract only*

#### **[Building global vaccine manufacturing capacity: Spotlight on Africa](#)**

Lewis John Rubin Thompson, Myriam Grubo, Martin Veller, Robyn Hayes Badenhorst, ... Wilmot Godfrey James  
Pages 4050-4056

### **Vaccines**

<https://www.mdpi.com/journal/vaccines>  
[Accessed 29 Jul 2023]

*Latest Articles*

*Open Access Communication*

#### **[Assessing the Influence of COVID-19 Vaccination Coverage on Excess Mortality across 178 Countries: A Cross-Sectional Study](#)**

by [Oliver Mendoza-Cano](#)

*Abstract*

The COVID-19 pandemic has had a devastating impact on global health, necessitating urgent and effective strategies to mitigate its consequences. Vaccination programs have been implemented worldwide to combat virus transmission and reduce the disease burden. This study aimed to investigate the relationship between COVID-19 vaccination coverage and all-cause excess mortality in 178 nations during the first two years of the pandemic. Multiple regression analysis, after adjusting for life expectancy at birth, confirmed a significant association between higher vaccination coverage and lower all-cause mortality rates ( $\beta = -106.8$ , 95% CI  $-175.4$  to  $-38.2$ ,  $p = 0.002$ ). These findings underscore the importance of vaccination campaigns in reducing overall mortality during the COVID-19 pandemic. Evidence-based decision making and resource allocation can benefit from this information, facilitating the optimization of vaccination strategies for maximal impact on mortality reduction. Further research and continuous monitoring are crucial to understanding the long-term effects of vaccination coverage on population health in the ongoing pandemic.

### **Value in Health**

July 2023 Volume 26 Issue 7 p957-1138  
<https://www.valueinhealthjournal.com/current>  
[Reviewed earlier]

.....  
.....

**Contents [click to move among sections]**

:: [Milestones, Perspectives](#)  
:: [WHO](#)  
:: [Organization Announcements](#)  
:: [Journal Watch](#)  
:: [Pre-Print Servers](#)

.....  
.....

**Pre-Print Servers**

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>  
[Accessed 29 Jul 2023]  
*Selected Research*  
[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>  
[Accessed 29 Jul 2023]  
[Filter: All articles]  
*Selected Research*

**[Parental intention, attitudes, beliefs, trust and deliberation towards childhood vaccination in the Netherlands in 2022: Indications of change compared to 2013](#)**

Marthe Knijff, Alies van Lier, Maartje Boer, Marion de Vries, Jeanne-Marie Hament, Hester E. de Melker  
medRxiv 2023.07.24.23291934; doi: <https://doi.org/10.1101/2023.07.24.23291934>

**[Attitudes and Perceptions of Medical Researchers Towards the Use of Artificial Intelligence Chatbots in the Scientific Process: A Protocol for a Cross-Sectional Survey](#)**

Jeremy Y. Ng, Sharleen G. Maduranayagam, Cynthia Lokker, Alfonso Iorio, R. Brian Haynes, David Moher  
medRxiv 2023.07.26.23293211; doi: <https://doi.org/10.1101/2023.07.26.23293211>

**[The historical fingerprint and future impact of climate change on childhood malaria in Africa](#)**

Colin J. Carlson, Tamma A. Carleton, Romaric C. Odoulami, Christopher H. Trisos  
medRxiv 2023.07.16.23292713; doi: <https://doi.org/10.1101/2023.07.16.23292713> Revision

**[Factors influencing COVID-19 vaccination decision-making among African American and Hispanic pregnant and postpartum women in Deep South](#)**

Ran Zhang, Tiffany Byrd, Shan Qiao, Myriam E. Torres, Xiaoming Li, Jihong Liu  
medRxiv 2023.07.20.23292951; doi: <https://doi.org/10.1101/2023.07.20.23292951>

**[Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: a prospective population-based study in rural Bangladesh](#)**

Roly Malaker, Md Hassanuzaman, Hafizur Rahman, Rajib Chandra Das, Naito Kanon, Senjuti Saha, Yogesh Hooda, Arif M Tanmoy, Sowmitra Ranjan Chakraborty, Shampa Saha, Maksuda Islam, Gary L. Darmstadt, Abdullah H Baqui, Mathuram Sathosam, Shams El-Arifeen, Cynthia G Whitney, Samir K Saha  
medRxiv 2023.07.23.23292706; doi: <https://doi.org/10.1101/2023.07.23.23292706>

**[The Political Division toward COVID-19, Vaccines, Contact Tracing Apps, and A Future Pandemic Scenario in the United States: A Survey Result from A National Representative Sample](#)**

Haijing Hao, Garrett Smith, Yunan Chen, Mainack Mondal, Po-Shen Loh, Staci Smith, Xinru Page  
medRxiv 2023.07.20.23292950; doi: <https://doi.org/10.1101/2023.07.20.23292950>

**[Artificial Intelligence in Biomedicine: Systematic Review](#)**

Irene S. Gabashvili  
medRxiv 2023.07.23.23292672; doi: <https://doi.org/10.1101/2023.07.23.23292672>

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Accessed 29 Jul 2023]

*[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]*

***We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.***

[We are temporarily suspending active coverage of this resource due to "posting pollution"]

**Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 29 Jul 2023]

*Selected Research*

*Research Article Open Access*

**[REVISED- Medical debt during epidemics: A case for resolving the situation in low- and middle-income countries such as Kenya](#)** [version 2; peer review: 4 approved with reservations]

Tom Obengo

*Software Tool Article Open Access*

**[Predictive Clinical Neuroscience Portal \(PCNportal\): instant online access to research-grade normative models for clinical neuroscientists.](#)** [version 1; peer review: awaiting peer review]

Pieter Barkema, Saige Rutherford, Hurng-Chun Lee, Seyed Mostafa Kia, Hannah Savage, Christian Beckmann, Andre Marquand



## *Abstract*

**Background:** The neurobiology of mental disorders remains poorly understood despite substantial scientific efforts, due to large clinical heterogeneity and to a lack of tools suitable to map individual variability. Normative modeling is one recently successful framework that can address these problems by comparing individuals to a reference population. The methodological underpinnings of normative modelling are, however, relatively complex and computationally expensive. Our research group has developed the python-based normative modelling package Predictive Clinical Neuroscience toolkit (PCNtoolkit) which provides access to many validated algorithms for normative modelling. PCNtoolkit has since proven to be a strong foundation for large scale normative modelling, but still requires significant computation power, time and technical expertise to develop.

**Methods:** To address these problems, we introduce PCNportal. PCNportal is an online platform integrated with PCNtoolkit that offers access to pre-trained research-grade normative models estimated on tens of thousands of participants, without the need for computation power or programming abilities. PCNportal is an easy-to-use web interface that is highly scalable to large user bases as necessary. Finally, we demonstrate how the resulting normalized deviation scores can be used in a clinical application through a schizophrenia classification task applied to cortical thickness and volumetric data from the longitudinal Northwestern University Schizophrenia Data and Software Tool (NUSDAST) dataset.

**Results:** At each longitudinal timepoint, the transferred normative models achieved a mean[std. dev.] explained variance of 9.4[8.8]%, 9.2[9.2]%, 5.6[7.4]% respectively in the control group and 4.7[5.5]%, 6.0[6.2]%, 4.2[6.9]% in the schizophrenia group. Diagnostic classifiers achieved AUC of 0.78, 0.76 and 0.71 respectively.

**Conclusions:** This replicates the utility of normative models for diagnostic classification of schizophrenia and showcases the use of PCNportal for clinical neuroimaging. By facilitating and speeding up research with high-quality normative models, this work contributes to research in inter-individual variability, clinical heterogeneity and precision medicine

## *Systematic Review Open Access*

**[UPDATEA living mapping review for COVID-19 funded research projects: final \(27 month\) update](#)** [version 10; peer review: 2 approved]

*Previously titled: A living mapping review for COVID-19 funded research projects: two year update*  
Adrian Bucher, et al.

## *Abstract*

**Background:** The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic.

**Methods:** The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th October 2022 the database contains 20,006 projects, funded by 351 funders, taking place across 157 countries representing an investment of at least \$7.4 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers.

This living mapping review aims to supplement the database by providing an open, accessible, and

frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analyses are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio.

Results: In this final version ten analysis, we provide an updated detailed descriptive analysis of the database (on data from three months after version nine) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations, and research locations (with a focus on resource-limited countries).

Conclusions: As the global research response to COVID-19 plateaus, this living mapping review has helped both funders and researchers to prioritise resources and review investments.

\* \* \* \*

### **Think Tanks**

**Brookings** [to 29 Jul 2023]

<http://www.brookings.edu/>

*Latest Research [Selected]*

*No new digest content identified.*

**Center for Global Development** [to 29 Jul 2023]

<https://www.cgdev.org/>

*All Research [Selected]*

*No new digest content identified.*

**Chatham House** [to 29 Jul 2023]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*Research paper*

#### **China's new scientists**

Achieving Xi Jinping's ambitious agenda of self-reliance in critical technologies will become all the more difficult as the space for creative thinking within China narrows, and opportunities diminish for Chinese scientists to work with peers internationally.

24 July 2023

**Council on Foreign Relations** [to 29 Jul 2023]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 29 Jul 2023]

<https://www.csis.org/>

*Selected Reports, Events*

*No new digest content identified.*

**Kaiser Family Foundation** [to 29 Jul 2023]  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*  
*No new digest content identified.*

**McKinsey Global Institute** [to 29 Jul 2023]  
<https://www.mckinsey.com/mgi/overview>  
*Latest Research*

**[Generative AI and the future of work in America](#)**

July 26, 2023 – Multiple forces are set to fuel growth in certain occupations and erode jobs in others.

**ODI [Overseas Development Institute]** [to 29 Jul 2023]  
<https://odi.org/en/publications/>  
*Publications [Selected]*  
*No new digest content identified.*

**Pew Research Center** [to 29 Jul 2023]  
<https://www.pewresearch.org/>  
*Latest Publications [Selected]*  
*No new digest content identified.*

**Rand** [to 29 Jul 2023]  
<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*No new digest content identified.*

**Urban Institute** [to 29 Jul 2023]  
<https://www.urban.org/publications>  
**[New Research Publications - Selected](#)**

*Research Report*

**[Advancing Vaccine Equity through Community-Based Organizations](#)**

July 26, 2023

The Centers for Disease Control and Prevention (CDC) launched the Partnering for Vaccine Equity (P4VE) program in 2020 to address racial and ethnic disparities in adult immunization rates, particularly for COVID-19 and influenza. In 2021, P4VE directed \$156 million to over 500 national, state, and community-based organizations (CBOs) to improve equitable access to vaccination in communities by promoting vaccine confidence and addressing barriers to vaccination opportunities.

The Urban Institute is partnering with CDC to support a subset of CBOs participating in the P4VE program. In the first year of the P4VE initiative (April 30, 2021, to April 29, 2022), the Urban Institute provided grant subawards and tailored program support and technical assistance to 29 CBOs. This

report presents findings from an evaluation of CBOs' performance on P4VE program objectives in the first year, including challenges and successes CBOs experienced in their efforts to improve vaccine equity.

**World Economic Forum** [to 29 Jul 2023]

<https://agenda.weforum.org/news/>

Media

**Macroeconomic and Geopolitical Conditions Pose Severe Risks to Organizations, say Chief Risk Officers**

News 26 Jul 2023

- Geopolitical and geoeconomic relations between major economies are set to experience significant volatility over the next six months, according to the World Economic Forum's Chief Risk Officers community
- New survey suggests 85% of CROs expect continued shocks in economic and financial conditions
- Armed conflicts and regulatory changes are also cited as potential threats to organizations
- Over 75% of CROs believe the use of AI technologies poses reputational risks to their organisation
- For more information, read the white paper [here](#)

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*  
\* \* \* \*